DUBLIN--(BUSINESS WIRE)--The "Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease" report has been added to ResearchAndMarkets.com's offering.
The T2DM pipeline is large with more than 560 products in active development, which accounts for almost a third of the metabolic disorders pipeline. This pipeline is dominated by products acting on G protein coupled receptors (GPCR) and protein kinases.
First-in-class products have the greatest potential in terms of development and commercial prospects. Among the pipeline products, 152 are first-in-class, which act on 95 distinct first-in-class targets. In line with the overall pipeline, first-in-class innovation is dominated by products acting on GPCRS and protein kinases. Additionally, there is a strong representation of first-in-class products at the Preclinical development stage.
- Requirement for new types of therapeutics to add to already complex treatment algorithms for severe T2DM
- What are the most important etiological risk factors and pathophysiological processes implicated in T2DM?
- What is the current treatment algorithm?
- How effective are current therapies for these indications, and how does this impact prognosis? What are the side effects associated with these treatments?
- The T2DM pipeline is dominated by G-protein-coupled receptors (GPCRs) and protein kinases
- Which molecule types and molecular targets are most prominent in the T2DM pipeline?
- Which first-in-class targets are most promising?
- How does the level of first-in-class innovation change within different target classes?
- How does first-in-class target diversity differ by stage of development and molecular target class?
- The deals landscape is active and dominated by products that target GPCRS and protein kinases
- Which molecular types/molecular target groups attract the highest deal values?
- How has deal activity fluctuated over the past decade?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?
- Competitive Market Landscape Driven by Rising Prevalence
- Large and Diverse Pipeline Dominated by Products Acting on G Protein Coupled Receptors (GPCR) and Protein Kinases
- Strong Opportunities for Investment in First-in-Class Products
The Case for Innovation
- Growing Opportunities for Biologic Products
- Diversification of Molecular Targets
- Innovative First-in-Class Product Developments Remain Attractive
- Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation
- Sustained Innovation in Type 2 Diabetes Mellitus
Key Topics Covered:
1 Table of Contents
2 Executive Summary
3 The Case for Innovation
4 Clinical and Commercial Landscape
5 Assessment of Pipeline Product Innovation
6 Signaling Network, Disease Causation and Innovation Alignment
7 First-in-Class Molecular Target Evaluation
8 Strategic Consolidations
For more information about this report visit https://www.researchandmarkets.com/research/2h58q2/2018_frontier?w=4